IAC regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} Idarubicin-Cytarabine-Cladribine regimen | {{SK}} Idarubicin-Ara C-Cladribine regimen; Idarubicin-Cytarabine-Cladribine regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[idarubicin]], [[Cytarabine|cytarabine (Ara-C)]], and [[cladribine]] used to treat [[acute myelogenous leukemia]]. | {{PAGENAME}} refers to a regimen consisting of [[idarubicin]], [[Cytarabine|cytarabine (Ara-C)]], and [[cladribine]] used to treat [[acute myelogenous leukemia]].<ref name="pmid14632771">{{cite journal| author=Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C et al.| title=Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. | journal=Br J Haematol | year= 2003 | volume= 123 | issue= 5 | pages= 810-8 | pmid=14632771 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14632771 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 16: | Line 16: | ||
==Indications== | ==Indications== | ||
* [[Acute myelogenous leukemia]] | * [[Acute myelogenous leukemia]]<ref name="pmid14632771">{{cite journal| author=Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C et al.| title=Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. | journal=Br J Haematol | year= 2003 | volume= 123 | issue= 5 | pages= 810-8 | pmid=14632771 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14632771 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 13:40, 27 March 2015
|
WikiDoc Resources for IAC regimen |
|
Articles |
|---|
|
Most recent articles on IAC regimen Most cited articles on IAC regimen |
|
Media |
|
Powerpoint slides on IAC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on IAC regimen at Clinical Trials.gov Clinical Trials on IAC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on IAC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on IAC regimen Discussion groups on IAC regimen Patient Handouts on IAC regimen Directions to Hospitals Treating IAC regimen Risk calculators and risk factors for IAC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for IAC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Idarubicin-Ara C-Cladribine regimen; Idarubicin-Cytarabine-Cladribine regimen
Overview
IAC regimen refers to a regimen consisting of idarubicin, cytarabine (Ara-C), and cladribine used to treat acute myelogenous leukemia.[1]
Regimen
IIdrarubicin
ACytarabine (Ara-C)
CCladribin
Indications
References
- ↑ 1.0 1.1 Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C; et al. (2003). "Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study". Br J Haematol. 123 (5): 810–8. PMID 14632771.